devinder pal - catalyst pharma consulting prescription for devinder pal catalyst pharma consulting
Post on 15-Jan-2016
226 views
TRANSCRIPT
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
prescription for
Devinder PalCatalyst Pharma Consulting
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Prescription for Health Or Death?
Flow of Presentation
1) Backdrop – Indian Pharma Industry
and Applicable Drug Laws
2) Various Counterfeit Drugs’ Definitions & resulting confusion?
3) What is the Extent of the Menace?
4) What are the Key Contributing Factors?
5) Which are the Target Products & Markets?
6) What needs to be done… and by whom?
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Serendipity & Growth Of Indian Pharma Industry
As a serendipitous gain Indian Pharma Industry has witnessed
a Phenomenal growth. In spite of
Or rather because of the Red tape and bureaucracy
that respected only Process Patents,
Imposed import restrictionsand capacity constraints on multinationals.
Incidentally these restr
ictions
are already out-dated in
today’s Global In
dia
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
India-from Zero To Hero
When India won Independence in 1947, it depended entirely on imports
Now about 20% of finished generics & OTC drugs in the US come from India
India has the largest number of US FDA approved plants outside US – some plants, I dare say, are superior to some in the US.
India’s exports exceed domestic consumption India exported $800 million worth of APIs and formulations
to the US in 2006 (China $675 million) India Pharma Industry is 4th largest in the World in terms of
volume , but 13th in value US FDA is evaluating options of opening its offices in India By 2012 India’s export s will be double of its domestic sale
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
MON # COMPANY NOW*1 1 GLAXO 12 2 CIPLA 23 3 RANBAXY 34 4 NICHOLAS 45 5 SUN PHARMA 56 6 DR.REDDY'S 67 7 ZYDUS-CADILA 79 8 AVENTIS 88 9 ABBOTT 910 10 ALKEM 10
The Top 10 Now & Where They Came From
Now only 3 MNCs in top
10
- Despite Mergers.
7 are Indian!
Once upon a timeAlmost all of the Top 10 were MNCs
(Sarabhai & Alembic)
Glaxo+BW+SKB+
Biddle Swayer
HMR+Roussel+RPR
Abbott + Boots
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
COMPANY NOW* 197111 WOCKHARDT 11 ?12 ARISTO PHARMA 12 ?13 LUPIN LABS 13 ?14 NOVARTIS 14 715 PFIZER 15 6 or 816 TORRENT PHARMA 16 ?17 ALEMBIC 17 418 U.S.V. 19 CADILA PHARMA 1920 UNICHEM LABS 20
* ORG Nov .2002
The next 10 now & where they came from
Pfizer+Warner +PD
Sandoz + Ciba
From Hero
to
Villain
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
India – From Hero To Villain
India is now accused of being the world leader in counterfeit drugs trade!
Some say 30 - 35 % of the Indian Pharma turnover is of spurious drugs (Highest in Bihar, UP, & west Bengal)
Perhaps exaggerated numbers –
perhaps not … I will revert on this later.First a brief introduce to the applicable
Indian Laws
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
India -Non Uniformity Of Enforcement Of Drug Laws Is A Reality
In India implementation of the Drugs & Cosmetic Act 1940 is the concerned State’s responsibility
Unfortunately the quality of enforcement in many States has been far from satisfactory.
Non-uniformity in the interpretation of the provisions of the laws, their implementation, and the varying levels of competence of the regulatory officials are the main reasons for this less than satisfactory performance.
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
India - Punishment As Per The Drugs Act
Manufacturer of a spurious/counterfeit drug can be punished with life imprisonment.
Unfortunately no one has been awarded this punishment so far !!!
We all know there is no greater deterrent than a ‘severe’, ‘sure’ and ‘swift’ punishment.-
Unhappily, Indian legal system cannot claim ‘swiftness’ as its virtue
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Indian FDA’s handicaps
Indian Regulatory bodies have not been able to keep pace with the phenomenal growth and developments in Indian Pharma space
The Mashelkar Committee concluded that the problems in the regulatory system in the country were primarily due to inadequate or weak drug control infrastructure at the State and Central level,
Inadequate testing facilities Insufficient Inspectors, non-uniformity of enforcement, lack of
specially trained cadres for specific regulatory areas, Virtually, non-existence of data bank.
Yet, despite many handicaps the Indian FDA has been doing a commendable job
So much for the backdrop of the Indian Pharma industry
Let’s now define Counterfeit drugs – since there seem be more than one definitions
First the US FDA definition.
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Definition of Counterfeit DrugsUS-FDA
The Food and Drug Administration, USA defines counterfeit drug as :
“A drug which, or the container of which, or labeling of which, without authorization, bears the trademark, trade name, other identifying mark, imprint or device or any likeness there of , a drug manufacturer, processor, packer, or distributor, other than the person, or persons who in fact manufactured, processed, packed, or distributed such drug and which thereby falsely purports, or is represented to be the product of, or to have been packed or distributed by such other drug manufacturer, processor, packer, or distributor.”
Please note : Sub-standards are not included , nor is IPR violations due to smuggling from across country`
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
FDA Warns Consumers about Counterfeit Drugs from Multiple Internet Sellers May 1, 2007
Internet is perhaps one of the largest route of selling counterfeit drugs. I am sure like me, you get any number of offers to get cheap drugs through the
net. My last count was 21 sites
USFDA does not permit this, but has been by and large helpless – except cautioning the public
The Food and Drug Administration (FDA) has cautioned U.S. consumers about dangers associated with buying prescription drugs over the Internet.
This alert was issued (May 1, 2007) based on information the agency received showing that 24 apparently related Web sites may be involved in the distribution of counterfeit prescription drugs .
None of the capsules ordered off the Web sites contained , the active ingredients.
Some other samples of drug product obtained from two of the Internet orders were composed of only talc and starch.
Though, as placebo effect some counterfeit Viagara, that contained no active worked well with some!
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
WHO DefinitionAccording to WHO a counterfeit medicine is one
which, is deliberately and fraudulently mislabeled with respect to identity and/or source.
Counterfeiting applies to both branded and generic products.
Counterfeit products may include products With correct ingredients OrWith wrong ingredients, OrWithout active ingredients, OrWith insufficient active ingredient, Or With fake packaging.
This definition is wider – as sub-standards get included
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Counterfeit & Substandard Medicines WHO
WHO recognizes that:Counterfeit medicines are a part of the broader
phenomenon of substandard pharmaceuticals – medicines manufactured below established standards of quality and therefore dangerous to patients’ health and ineffective for the treatment of diseases.
A substandard product may also be counterfeit.Though, all substandard products are not
necessarily counterfeitsA counterfeit product may or may not be
Substabdard – though more often than not, it is so
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
What is a Counterfeit drug?Wikipedia
A counterfeit drug is a medication which is produced and sold with the intent to deceptively represent its origin, authenticity or effectiveness.
A counterfeit drug may be one which does not contain active ingredients, contains an insufficient quantity of active ingredients, or contains entirely incorrect active ingredients (which may or may not be harmful), and which is typically sold with inaccurate, incorrect, or fake packaging.
Fake medicines and generic drugs which are deliberately mislabeled in order to deceive consumers are therefore counterfeit
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
What is a Counterfeit drug (contd.)?From Wikipedia
Counterfeit drugs can generally be classified by the following characteristics:
Re-labeled drugs that were previously expired, defective or otherwise deemed unfit for use;
Drugs wherein the active ingredient is fraudulently diluted;
Drugs wherein the active ingredient is adulterated; Drugs wherein the active ingredient is substituted; Falsely-labeled substances of any composition
wherein the active ingredient is completely misrepresented; and
Falsely-labeled substances whose combined active ingredients meet one or more of the preceding criteria.
Very lucid - similar to WHO
definition –
includes sub-sta
ndard under
Counterfeits
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Spurious & Counterfeit
The Indian Drugs Act does not use the word Counterfeit!
It uses the word “Spurious” Drugs
Here is the definition
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Definition of Spurious DrugsIndian Drugs Act
A drug shall be deemed to be spurious if it is manufactured under a name which belongs to another drug, or
If it is an imitation of, or is substitute for, another drug, or resembles another drug in a manner likely to deceive, or
Bears upon its label or container the name of another drugunless it is plainly and conspicuously marked so as to revealits true character and its lack of identity with such other drug, or
If the label or container bears the name of an individual, orCompany purporting to be the manufacturer of the drug,which individual or company is fictitious or does not exist, or
If it has been substituted wholly or in part by another drug or
Substance, or If it purports to be the product of a manufacturer of whom
it is not
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Counterfeit is not defined… but
Even though the word Counterfeit is not Even though the word Counterfeit is not defined, the Indian Drugs Act’s definition of defined, the Indian Drugs Act’s definition of spurious drug is spurious drug is wide enough to cover wide enough to cover Counterfeit drugs. Counterfeit drugs.
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Prescription for Health Or Death?
What is the Extent of the Menace?
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Extent of Spurious Drugs - No Validated DataMashelkar committee report Nov.2003
The reported extent ranged widely between 0.5% (based on the cases analyzed and 35% (ascribed to WHO Studies).
However, WHO itself had written in response to a query from the Indian Government that:
‘There is no actual study by WHO, which concludes that 35% of World’s spurious drugs are produced in India’.
Some estimation of the quantum of spurious drugs in the market quoted is available based on the cases detected in selected pockets and regions in the country. Validation of the claims made by several agencies was not available as concrete and authenticated evidence.
The Mashelkar Committee came to the conclusion, after examining all the data and reports at hand: ‘there was an absence of a scientifically andstatistically designed investigation, which could give a realistic
estimate of the menace of spurious drugs’.
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Yet another set of numbers!
Deputy Drugs Controller India for West Zone (he has since moved to number one post in FDA) has said:His office had taken over 4000 samples of eight
to nine brands Out of which only two were found counterfeit.
He added that the percentage of counterfeiting was as low as 0.01 % in
West zone
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Estimates (Guess)Estimates and Statistics
Recent sting operation by a TV channel in India concluded:30 % of all drugs sold in India were spurious!!! This conclusion was based on the clandestine
operations unearthed by them.The TV showed bottles of a cough syrup being filled …
one bottle at a time… by using a funnel & a beaker… no machine!
At this rate I guess (‘light heartedly’ speaking) the whole of adult Indian population may be needed to produce what might constitute 30 % of country’s consumption!
Yet a man in the street now believes the 30 % number that has resurfaced on the popular channel that is usually responsible in reportage.
Statistics and estimates are like Bikinis;
What they reveal is interesting… but what they hide is vital Some are uncharitable enough to say: ‘There are lies, damn lies, and Statistics’. We all know, one can use statistics to prove anything, by selecting sample size and source`
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
50 : 50
One ChickenOne Horse
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Estimates of Anti-counterfeiting group (including Substandard)
According to the anti-counterfeiting group, counterfeit drugs constitute 6 % of world-wide drug sales in 2000
The group estimated the following figures for some countries:
Brazil: 20%, Nigeria 60-70%, Indonesia: 25%, Senegal: 10 times the regular market; India: 20%, Pakistan: 20-50%, China: the largest producer of sub-standard drugs in the
world
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Estimates…Estimates!!!
Precise data on extent of counterfeit medicines is difficult to obtain.
So we have Estimates … or shall we say (Guess)estimates…
As is obvious, some of the reasons for wide variation in numbers are: Huge differences between regions, Dramatic variations within a country i.e. city versus rural areas,
city versus city Counterfeiting is greatest in those regions where the regulatory and
legal oversight is weakest.
The above is certainly true for India – I have every reason to believe that this is universal truth
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
To Sum it up Estimates Vary Widely
We have seen estimates of counterfeit drugs vary from a fraction of 1 % to 50 %
Additional complicating factors are: Some numbers are based only on ‘Counterfeits”
Others also include sub-standard drugs Products not complying with the label claims:
Intentional: lower end the range (95% to 105%)Unintentional ‘potency or bioavailability or other
key parameters effected’ due to bad storage or transportation or due to undetected variation in quality of inputs or process
Ignorance (diethyl glycol),
Yet others also include: IPR violations, or Trademark violations Even Similar sounding Brand names
Even though these may be due to cross border smuggling – from a country producing the product as per applicable laws.This is the root cause of conflicting numbers!
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Perception & Reality
There are significant gaps between Perception and reality
There are differences in definition This is bound to throw up
different numbers, andsend us barking up the wrong tree!
No doubt everyone is looking at the ElephantSome are looking at the Tusk, Some others at the TailAnd yet some others at the legs of the ElephantNo wonder there are differences in perceptions!
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Serious Cause for Worry
Whatever the %age… High or low percentage … counterfeit & spurious
drugs are serious cause for worryThe US based Centre for Medicines predicts that
counterfeit drug sales will reach US$ 75 billion globally in 2010, an increase of more than 90% from 2005
Other predictions forecast 10 % of World market will be Counterfeit drugs
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Prescription for Health Or Death?
What are the Key Contributing Factors?
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Counterfeiting of commercial products has been in exisitence… ever since!
Greed is a common human weakness – not confined to any religion or region
The problem of spurious and counterfeiting is universal
Since consumers and doctors are unable to independently assess the quality, safety and efficacy. the consequences of ineffective regulatory oversight can be deadly to patients.
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
What are the key factors contributing to proliferation?
Very remunerative trade Weak penal action tardy court proceedings Availability of improved printing technology that makes
counterfeiting easier. Lack of coordination between various agencies Inadequate cooperation between stakeholders … bordering on
callousness (Law and Order?) Lack of control by importing/exporting countries Wide spread corruption and conflict of interests Non-uniformity of enforcement standard followed by the drug
control authorities within a country, and country to country variations.
Large scale sickness in small scale pharmaceutical industry Apathy to anti-counterfeiting measures
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
What are the Target Products & Markets?
Only a handful of top selling brands are attractive targets – fast moving and high margins are the key words
The production of counterfeit drugs does not occur in large infrastructures or facilities. The majority of the counterfeiters apprehended so far, carried out their activities in ordinary households, small cottage industries, or in backyards.
Trade in fake medicines is more prevalent in countries: with weak drug regulation and enforcement, Or scarcity or erratic supply of basic medicines, Or unregulated markets Or unaffordable prices, Or poor law enforcement
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Lack of Foresight of the Industry & Profession!
Our lack of foresight that Technology & internet will make the task easier.Our lack of foresight of developing and using anti-
counterfeiting measures - to make it difficult if not impossible.
Lack of effective deterrents punishment, combined with poor enforcement - virtually inviting anybody wanting to get rich quickly, to have a field’s day.
Lack of coordinated preventive actions – not even at country level, leave alone at International level
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
We forgot thatAn open door tempts even a saint!
We forget Prevention is always better than Cure! What did we do to prevent temptation getting better of unscrupulous elements?
Not enough (Virtually nothing!)We did not foresee that technology will make counterfeiting a
child’s play.We have been complacent … We forget that open door tempts even a ‘saints’ … In the absence of using anti-counterfeiting measures,
we are virtually leaving diamonds on platter on the roadside, expecting that no one will take them way!
No security guard– not even a lock on the Jewelers store
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Prescription for Health
6. What needs to be done… and by whom?
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Learning from experience
CDs, VCD, DVD piracy in IndiaLaw and Order problem … much like we in
Pharma industry are sayingIndustry leaders got togetherEvolved a strategyPooled monetary and other resourcesHired professionalUsed police help… but the manufacturers
were in driving seat
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
What needs to be done?
Multi-pronged approach at country’s FDA level
Strengthen Drug Administration Increase sampling & analysis Involve Police in investigation Coordinate actions of all stakeholders Consumer Education
Collect intelligence Medical RepresentativesDoctors & Hospitals Distribution ChannelsOther investigating agencies Profile on sick units Associations
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
What needs to be done -2 ?
Creating awareness amongst: Medical profession, and above allPatients & Public at large
Awareness ofMenace & consequencesAnti-counterfeiting devices
(Meaningless unless educated on
What? How to?)
Identifying countries / regions of higher incidence – to permit prioritization of areas needing higher dose of preventive, punitive actions / resources
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Who are best placed to detect?
There are only two victims of counterfeit drugs – consumer and the manufacturer. The rest are not real sufferers
Manufacturers, wholesalers, re-packagers, pharmacists and PSRs are in the best position to detect counterfeit drugs.
They should play a proactive role, and be required by law to report their suspicions to the relevant authorities.
Unfortunately the main stake holders have done precious little – so far
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Strategy – Multi-country Coordinated Actions
Multi-country (WHO - IMPACT?) coordinated attack to deal with this menace
Arrive at a common definition of Counterfeit drugs Survey to determine
Extent of problem Vulnerable countriesVulnerable areas / regions
Networking for sharing of intelligence structured mechanism for sharing information Designate a contact persons in regulatory
agencies and industry Multi-pronged coordinated attack to track & book
the culprits
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Everybody, Somebody, Anybody, Nobody !
There were four colleagues: ‘Everybody’, ‘Somebody’, ‘Anybody’, and ‘Nobody’
And there was a job to be done: ‘Everybody’ knew how to do it, he was confident ‘Somebody’ will do it ‘Somebody’ was sure ‘Anybody’ will do it ‘Anybody’ felt ‘Everybody’ will do it The result: ‘Nobody’ did it !!!
We are behaving no different from this story! The Pharmacist says it is Doctor’s responsibility The Doctor says it is the manufacturer's responsibilityManufacturers say it is Govt’s responsibility Everyone is passing the buck. What about poor patient? Robert Richter from the Movie
“Pills For Exports only” Before I endBrief generic coverage of Anti counterfeiting measures
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Generic Description Of Anti-counterfeiting Measures
Protection
High
Packaging determined by features of the
product
Level 5
Level 4
Level 3
Level 2
Level 1
Legal Protection Features
Permits manufacturers to track & trace any form of brand attack
Features that require consume
involvement to confirm genuineness
Visual Identification feature – invites
consumer to participate in protecting himself
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Giving a Counterfeit to a sick person is akin to
sentencing him to death
It is n
o brainer
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Perfect Murder
Administering counterfeits is “akin to a perfect crime, because fake medicines look like the real thing and evidence is gone because a patient is always presumed to have died from the disease, rather than the drug. And the mastermind is never caught," Ranjit Shahani
To Catch the CulpritAll Stake holders must play their role
Unfortunately there is no perfect bullet
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Counterfeiting
Offers
Red Carpet for
Quick buck
We must do our bit to make it tough for them
and
ensure to
death by
hanging
from the nearest lamp post!
Devinder Pal - Catalyst Pharma ConsultingDevinder Pal - Catalyst Pharma Consulting
Devinder Pal www.CatalystPharmaConsult.com